Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis
出版年份 2012 全文链接
标题
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 23, Issue 12, Pages 3110-3116
出版商
Oxford University Press (OUP)
发表日期
2012-06-29
DOI
10.1093/annonc/mds148
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
- (2011) J Cassidy et al. BRITISH JOURNAL OF CANCER
- Prediction of Survival by Neutropenia According To Delivery Schedule of Oxaliplatin–5-Fluorouracil–Leucovorin for Metastatic Colorectal Cancer in a Randomized International Trial (EORTC 05963)
- (2011) Pasquale F. Innominato et al. CHRONOBIOLOGY INTERNATIONAL
- Androgens Modulate Structure and Function of the Suprachiasmatic Nucleus Brain Clock
- (2011) Ilia N. Karatsoreos et al. ENDOCRINOLOGY
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- Circadian Timing in Cancer Treatments
- (2010) Francis Lévi et al. Annual Review of Pharmacology and Toxicology
- Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability
- (2010) Francis Lévi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Cancer Inhibition through Circadian Reprogramming of Tumor Transcriptome with Meal Timing
- (2010) X. M. Li et al. CANCER RESEARCH
- When Separate Is More Equal
- (2010) Nancy E. Adler JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Sex Differences in Phase Angle of Entrainment and Melatonin Amplitude in Humans
- (2010) Sean W. Cain et al. JOURNAL OF BIOLOGICAL RHYTHMS
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulation of circadian rhythms and hypothalamic-pituitary-adrenal axis: an overlooked interaction in cancer
- (2010) Pasquale F Innominato et al. LANCET ONCOLOGY
- Clocks not winding down: unravelling circadian networks
- (2010) Eric E. Zhang et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Circadian Rhythm in Rest and Activity: A Biological Correlate of Quality of Life and a Predictor of Survival in Patients with Metastatic Colorectal Cancer
- (2009) P. F. Innominato et al. CANCER RESEARCH
- Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX
- (2009) Kohei Shitara et al. EUROPEAN JOURNAL OF CANCER
- Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?
- (2009) René Adam et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- Gender-Related Survival Differences Associated with EGFR Polymorphisms in Metastatic Colon Cancer
- (2008) O. A. Press et al. CANCER RESEARCH
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group
- (2008) Matthias Schwab et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started